Where is the bottom??, page-108

It’s almost four months since the cabazitaxel enrolment and treatment was completed and data analysis commenced. It cannot be long now before the results are announced.


While I personally don’t expect vastly improved efficacy, due to the limits of the underlying drug, I do hope that safety and tolerability are greatly improved. That should be enough to make it the new standard of care (and push our share price back up). The Docetaxel results should not be far behind, and the large world market is there for the taking - depending on the results of course.